执照
医学
医疗急救
梅德林
大流行
病毒学
重症监护医学
家庭医学
2019年冠状病毒病(COVID-19)
流感减毒活疫苗
病毒性疾病
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
正粘病毒科
甲型流感病毒
2019-20冠状病毒爆发
流感大流行
作者
Julie Ostrowsky,Bruce G. Gellin,Marco Cavaleri,Joseph S. Bresee,Rajeev Venkayya,Rebecca Jane Cox,Stacey Schultz‐Cherry,Rosalind C. Hollingsworth,Kanta Subbarao,Cheryl Cohen,Ethan C. Settembre,Edward A. Belongia,John W. McCauley,Rino Rappuoli,Benjamin John Cowling,Jessica E. Taaffe,Natalie C. Vestin,Angela J Mehr,Angela K. Ulrich,Michael T. Osterholm
出处
期刊:Vaccine
[Elsevier BV]
日期:2026-09-18
卷期号:92: 129135-129135
标识
DOI:10.1016/j.vaccine.2026.129135
摘要
The Influenza Vaccines R&D Roadmap (IVR) Initiative was established to: (1) highlight the public health need for improved vaccines against pandemic and seasonal influenza; (2) raise the visibility of opportunities to create highly effective and rapidly produceable influenza vaccines; and (3) facilitate sustained investment in vaccine R&D. Incremental progress has been made in achieving many of the activities outlined in the IVR. However, without significant improvements in vaccine performance (efficacy, durability, ability to block virus transmission) and production (manufacturing speed, scale-up capacity, adaptability), we risk having to fight the next influenza pandemic with last century's technology. This report reviews remaining barriers to advanced development of vaccines for global use against seasonal and pandemic influenza and summarizes key priorities and activities for moving the influenza vaccine R&D enterprise forward.
科研通智能强力驱动
Strongly Powered by AbleSci AI